Quick Facts
| Property | Value |
|---|---|
| Category | Amylin Receptor Agonist |
| Risk Level | Moderate |
| Administration | Subcutaneous Injection |
| Typical Frequency | Once Weekly |
| Estimated Half-Life | Approximately 1 Week |
| Primary Research Interest | Appetite Suppression / Weight Reduction |
This material is provided strictly for educational and informational purposes related to peptide research and metabolic compounds. Cagrilintide is a biologically active investigational compound that may significantly affect appetite regulation and gastrointestinal signaling. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL
At this concentration:
• 250 mcg = 0.050 mL (5.0 units)
• 2.4 mg = 0.480 mL (48.0 units)
2. Route of Administration
Cagrilintide is most commonly administered as a subcutaneous injectable metabolic peptide compound.
- Primary Route: SubQ Injection
- Preferred Timing: Once weekly administration
- Administration Notes: Due to its extremely long half-life, split dosing throughout the week is generally considered unnecessary
3. Typical Research Protocols
- Product Strength: 5.00 mg/mL
- Typical Delivered Amount: 250 mcg weekly for 2 weeks, doubling every 2 weeks as tolerated up to a maximum of 2.4 mg
- Frequency: Once per week
- Cycle Length: Indefinite
- Special Notes: Cagrilintide is commonly discussed in combination with GLP-1 receptor agonists to maximize appetite suppression and metabolic effects. Due to its very long half-life, splitting the weekly dose is generally considered unnecessary and offers little practical benefit.
4. Summary
Cagrilintide is a long-acting amylin receptor agonist developed for appetite suppression and body weight reduction research.
The compound is frequently discussed alongside GLP-1 receptor agonists because of potentially complementary appetite-regulating effects.
5. Mechanism of Action
Cagrilintide mimics amylin signaling pathways involved in satiety, gastric emptying, and appetite regulation.
Potential downstream effects discussed in research include:
- Reduced appetite signaling
- Enhanced satiety
- Slower gastric emptying
- Reduced caloric intake
- Potential synergy with GLP-1 receptor agonists
Its extended half-life supports once-weekly administration patterns.
6. Potential Benefits
- Significant appetite suppression
- Reduced caloric intake
- Potential body weight reduction
- Possible synergy with GLP-1 compounds
- Reduced food preoccupation in anecdotal reports
7. Potential Risks / Side Effects
Moderate
- Nausea
- Vomiting
- Constipation
- Fatigue
- Dizziness
- Reduced appetite to problematic levels
- Potential gastrointestinal discomfort
- Limited long-term human safety data
8. Half-Life
Cagrilintide is commonly discussed as having an estimated half-life approaching approximately one week.
This extended duration is one reason why once-weekly administration protocols are widely discussed.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Pregnancy or breastfeeding
- Severe gastrointestinal disorders
- History of pancreatitis
- Severe eating disorders
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Metabolic disease and obesity literature
- Peer-reviewed incretin and amylin research journals
CKF Tide Tables 